MedTrace Logo

Efficacy and Safety Evaluation of Inhaleen Inhalation in Hospitalized COVID-19 Patients

NCT04793984 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2022-08-29

No results posted yet for this study

Summary

The current study will investigate the tolerability and efficacy of inhaled Carragelose® versus saline in hospitalized COVID-19 patients. As SARS-CoV-2 replicates readily in the lung, it is planed to apply Carragelose® in an inhalative form. Hospitalized COVID-19 patients with respiratory symptoms will inhale Inhaleen for 5 days.

Conditions

  • Covid19

Interventions

DEVICE

Carragelose

inhalation 3 times a day

DEVICE

NaCl

inhalation 3 times a day

Sponsors & Collaborators

  • Marinomed Biotech AG

    lead INDUSTRY

Principal Investigators

  • Arschang Valipour, MD · Karl Landsteiner Society; Clinic Floridsdorf

  • Georg-Christian Funk, MD · Karl Landsteiner Society, Clinic Ottakring

  • Wolfgang Hoeppler, MD · Gesundheitsverbund Klinik Favoriten

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-08
Primary Completion
2022-07-30
Completion
2022-07-30

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04793984 on ClinicalTrials.gov